Norethindrone and Voriconazole drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Norethindrone (norethindrone) and Voriconazole (voriconazole). Common drug interactions include intracranial pressure increased among females.

The phase IV clinical study analyzes what interactions people have when they take Norethindrone and Voriconazole. It is created by eHealthMe based on reports of 21 people who take the same drugs from the FDA, and is updated regularly.

What is Norethindrone?

Norethindrone has active ingredients of norethindrone. It is often used in birth control. eHealthMe is studying from 1,610 Norethindrone users. Check the latest studies of Norethindrone.

What is Voriconazole?

Voriconazole has active ingredients of voriconazole. It is often used in aspergillosis. eHealthMe is studying from 21,706 Voriconazole users. Check the latest studies of Voriconazole.



On Jul, 15, 2026

21 people who take Norethindrone and Voriconazole together, and have interactions are studied.

Norethindrone and Voriconazole drug interactions.

What are the common drug interactions of Norethindrone and Voriconazole, by gender? *:

female:

  1. Intracranial pressure increased (high pressure inside the skull and thus in the brain tissue and cerebrospinal fluid)
  2. Dilatation intrahepatic duct acquired
  3. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  4. Pneumonia
  5. Alanine aminotransferase increased
  6. Atrial thrombosis (blood clot that develops in an artery)
  7. Back pain
  8. Blood bilirubin increased
  9. Blood lactate dehydrogenase increased
  10. Flank pain (a distressing sensation experienced around the lower back and the upper abdomen)

male:

n/a

What are the common drug interactions of Norethindrone and Voriconazole, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Dilatation intrahepatic duct acquired
  2. Hepatotoxicity (chemical-driven liver damage)
  3. Venoocclusive liver disease (small veins in the liver are obstructed)
  4. Hypersensitivity
  5. Infusion related reaction
  6. Atrial thrombosis (blood clot that develops in an artery)
  7. Back pain
  8. Blood lactate dehydrogenase increased
  9. Flank pain (a distressing sensation experienced around the lower back and the upper abdomen)
  10. Haemolysis (breaking open of red blood cells and the release of haemoglobin into the surrounding fluid)

20-29:

  1. Cystitis haemorrhagic (blood in the urine and painful voiding)
  2. Haematuria (presence of blood in urine)
  3. Pain
  4. Paraesthesia (sensation of tingling, tickling, prickling, pricking, or burning of a person's skin with no apparent long-term physical effect)
  5. Pneumonia
  6. Respiratory failure (inadequate gas exchange by the respiratory system)
  7. Dilatation intrahepatic duct acquired
  8. Hepatotoxicity (chemical-driven liver damage)
  9. Venoocclusive liver disease (small veins in the liver are obstructed)

30-39:

n/a

40-49:

  1. Posterior reversible encephalopathy syndrome (posterior reversible encephalopathy syndrome (pres), also known as reversible posterior leukoencephalopathy syndrome (rpls), is a syndrome characterized by headache, confusion, seizures and visual loss)
  2. Sepsis (a severe blood infection that can lead to organ failure and death)
  3. Systemic inflammatory response syndrome (an inflammatory state affecting the whole body, frequently a response of the immune system to infection)

50-59:

n/a

60+:

  1. Alanine aminotransferase increased
  2. Blood bilirubin increased
  3. Dilatation intrahepatic duct acquired
  4. Hepatotoxicity (chemical-driven liver damage)
  5. Pain
  6. Tachycardia (a heart rate that exceeds the range of 100 beats/min)
  7. Venoocclusive liver disease (small veins in the liver are obstructed)

What are the existing conditions these people have? *

  1. Depression: 8 people, 38.10%
  2. Pain: 7 people, 33.33%
  3. Vaginal Bleeding: 4 people, 19.05%
  4. Adverse Drug Reaction: 3 people, 14.29%
  5. T-Cell Type Acute Leukaemia (a form of cancer of the white blood cells): 2 people, 9.52%

* Approximation only. Some reports may have incomplete information.

Do you take Norethindrone and Voriconazole?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Norethindrone and Voriconazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Norethindrone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Voriconazole:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Norethindrone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Voriconazole and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on norethindrone and voriconazole (the active ingredients of Norethindrone and Voriconazole, respectively), and Norethindrone and Voriconazole (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: